Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 12 ... Patients in the new study were taking aromatase inhibitors including Arimidex, Femara or Aromasin. Of the 300 patients enrolled in the study, 139 reported AI-related pain, with 75 ...
Subject: University of Pennsylvania School of Medicine
2009 JUN 1 ... Oncology is building upon the foundation of our marketed agents Sutent, Camptosar, and Aromasin. Our research is focused on bridging new insights into cellular targets and causative ...
2009 OCT 5 ... present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results ...
2009 OCT 5 ... that switching post-menopausal women with early breast cancer to the drug exemestane (Aromasin) after two or three years of tamoxifen rather than keeping them on tamoxifen for five ...
2007 JUL 2 ... from tamoxifen to the oral steroidal aromatase inhibitor exemestane (trade name: Aromasin) extended disease free survival at a minimal cost per person. In another of study of ...
2008 JUN 2 ... Data on the following compounds will also be presented at ASCO 2008: Aromasin(R) (exemestane), Camptosar(R) (irinotecan HCl), CP-868596, PF-3512676, PF-562271 and ...
2007 SEP 10 ... authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal ...
2007 JUN 19 ... published today in The Lancet shows for the first time that patients who switched to Aromasin after taking tamoxifen for two to three years were 17 percent more likely to survive and ...
2007 JUN 19 ... inhibitors (AIs), which includes Femara (letrozole), Arimidex (anastrozole), and Aromasin (exemestane). AIs have been recommended for the adjuvant (post-surgery) treatment of ...
2008 DEC 29 ... An interim analysis of a breast cancer prevention study using exemestane (Aromasin®) finds an "acceptable" level of bone loss.
The ongoing phase II study ...
2007 JUN 25 ... 39 percent), Vfend (up 26 percent), Viagra (up 11 percent), Zyrtec (up 10 percent), and Aromasin (up 33 percent), as well as strong revenues for two key new products- Chantix/Champix ...
2007 JUL 2 ... 39 percent), Vfend (up 26 percent), Viagra (up 11 percent), Zyrtec (up 10 percent), and Aromasin (up 33 percent), as well as strong revenues for two key new products- Chantix/Champix ...
2007 AUG 20 ... 39 percent), Vfend (up 26 percent), Viagra (up 11 percent), Zyrtec (up 10 percent), and Aromasin (up 33 percent), as well as strong revenues for two key new products- Chantix/Champix ...
2007 AUG 13 ... published today in The Lancet shows for the first time that patients who switched to Aromasin after taking tamoxifen for two to three years were 17 percent more likely to survive and ...
2007 SEP 17 ... published today in The Lancet shows for the first time that patients who switched to Aromasin after taking tamoxifen for two to three years were 17 percent more likely to survive and ...
2007 JUL 3 ... authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal ...
2008 SEP 8 ... for the generic and proprietary names of each AIs: anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) were evaluated using a 12-point score by a single assessor. The ...
